Subjects with psoriasis vulgaris in a chronic stable phase and with a plaque area of mild to moderate severity sufficient for six treatment fields located in up to three plaque areas. Chronic plaque psoriasis, or psoriasis vulgaris, is a chronic inflammatory skin disease characterised by well demarcated, erythematous, scaly plaques on the extensor surfaces of the body and scalp. Comparison of a treatment phase and a follow-up phase of short contact dithranol and calcipotriol in outpatients with chronic plaque psoriasis. TRANSFIGURE enrolled 198 patients with chronic moderate to severe plaque psoriasis, including significant nail involvement, randomized 1:1:1 to receive either Cosentyx 300mg, Cosentyx 150mg or placebo subcutaneously up to week 76. Creabilis issued results from a phase IIa trial of CT327 cream for psoriasis vulgaris (PV).
Psoriasis is a common chronic skin disorder typically characterized by erythematous papules and plaques with a silver scale, although other presentations occur. All topics are updated as new evidence becomes available and our peer review process is complete. As an example, one study of excimer laser therapy involved 124 patients with stable mild to moderate plaque psoriasis, of whom 80 completed the entire protocol 74. An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis. Study of KD025 Treatment in Subjects With Moderately Severe Psoriasis Vulgaris. Luma Light System Proof of Concept Study in Subjects With Mild to Moderate Psoriasis. This phase I, first-in-human, non-randomized, open-label study evaluated the short-term safety, pharmacokinetics, and clinical response of single, ascending, intravenous (IV) doses of anti-IL-12p40 in subjects with moderate-to-severe psoriasis vulgaris.
Phase 2. Planned study of KD025 in chronic graft-versus-host disease. KD025 in Psoriatic Arthritis. Find out information about Psoriasis vulgaris. occasionally acute but usually chronic and recurrent inflammation of the skin. (srss), occasionally acute but usually chronic and recurrent inflammation of the skin. A variety of treatments are used for patients with mild to moderate cases. In two phase 3 studies (AMAGINE-2 and AMAGINE-3), patients with moderate-to-severe psoriasis were randomly assigned to receive brodalumab (210 mg or 140 mg every 2 weeks), ustekinumab (45 mg for patients with a body weight 100 kg and 90 mg for patients 100 kg), or placebo. Specialties & Topics.
Treatment Of Psoriasis
This paper reviews the data supporting the use of alefacept in psoriasis and psoriatic arthritis. In a randomised, double blind, placebo controlled phase 3 study, patients with moderate to severe psoriasis vulgaris were treated with alefacept 15 mg monotherapy or placebo intramuscularly (IM) on a weekly basis for 12 weeks. Efficacy and safety of multiple courses of intramuscular alefacept in patients with chronic plaque psoriasis.